CREST-2 致力于对颈动脉支架植入术用于脑卒中一级预防进行严格评估

J. Meschia, Lloyd J. Edwards, Gary Roubin, Thomas G. Brott, B. Lal
{"title":"CREST-2 致力于对颈动脉支架植入术用于脑卒中一级预防进行严格评估","authors":"J. Meschia, Lloyd J. Edwards, Gary Roubin, Thomas G. Brott, B. Lal","doi":"10.1161/svin.123.001227","DOIUrl":null,"url":null,"abstract":"\n \n \n Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2)\n (\n study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators.\n \n \n \n \n The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices.\n \n \n \n The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial.\n \n \n \n The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.\n","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"66 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CREST‐2 Commitment to Rigorous Assessment of Carotid Stenting for Primary Prevention of Stroke\",\"authors\":\"J. Meschia, Lloyd J. Edwards, Gary Roubin, Thomas G. Brott, B. Lal\",\"doi\":\"10.1161/svin.123.001227\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2)\\n (\\n study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators.\\n \\n \\n \\n \\n The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices.\\n \\n \\n \\n The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial.\\n \\n \\n \\n The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.\\n\",\"PeriodicalId\":21977,\"journal\":{\"name\":\"Stroke: Vascular and Interventional Neurology\",\"volume\":\"66 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stroke: Vascular and Interventional Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1161/svin.123.001227\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke: Vascular and Interventional Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/svin.123.001227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

与其将颈动脉支架置入术和动脉内膜切除术视为对立的手术,不如将其视为互补的手术,有些患者更适合一种手术,而不是另一种。支架植入术和内膜剥脱术各自最适合获得最佳疗效的患者人群存在很大差异。因此,CREST-2(颈动脉血运重建、内膜剥脱术与支架植入术试验-2)研究被设计为两个独立的双臂随机试验,同时进行。其中一项试验比较有支架植入术和无支架植入术的强化医疗管理;另一项试验比较有内膜切除术和无内膜切除术的强化医疗管理。每项试验的招募目标是招募 1240 名无症状颈动脉狭窄≥70% 的患者,每组按 1:1 随机分配。为确保患者安全,使支架植入术在预防中风方面获得最大的净获益,CREST-2 采用了一套严格的程序来评估、监控和批准操作者加入试验。CREST-2 注册中心的建立是为了让申请的支架操作人员获得最新的经验。 CREST-2 注册中心是一项前瞻性、多中心、短期颈动脉支架治疗观察研究,允许使用多种设备。 该注册中心于 2014 年 9 月注册了第一例患者,截至 2023 年 10 月 2 日,共有来自 103 个不同临床中心的 207 名不同支架操作人员治疗了 9830 例患者。在这个由无症状(占队列的 61.1%)和有症状(占队列的 38.9%)患者组成的混合队列中,30 天卒中率为 1.8%,30 天卒中或死亡率合计为 2.6%。在 2016 年 3 月的高峰期,注册率达到了每月 142 例。截至 2023 年 10 月 20 日,CREST-2 支架植入试验仍有 104 例患者待登记。 注册中心为 CREST-2 试验组建了一支优秀的支架操作团队。在众多操作人员的持续支持下,我们预计将于 2024 年夏季完成注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CREST‐2 Commitment to Rigorous Assessment of Carotid Stenting for Primary Prevention of Stroke
Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2) ( study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators. The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices. The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial. The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Prognostication Following Aneurysmal Subarachnoid Hemorrhage: The Modified Hunt and Hess Grading Scale Intra‐arterial Selective Bevacizumab Administration in the Middle Meningeal Artery for Chronic Subdural Hematoma: An Early Experience in 12 Hemispheres Sex Disparities in Mortality After Endovascular Therapy in Large Core Infarcts Predicting Recanalization Failure With Conventional Devices During Endovascular Treatment Related to Vessel Occlusion Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1